Homozygous CD19 mutations lead to an antibody deficiency due to disruption of the CD19 complex and consequent impaired signaling by the B-cell antigen receptor. We studied the effects of heterozygous CD19 mutations on peripheral B-cell development and antibody responses in a large family with multiple consanguineous marriages. Sequence analysis of 96 family members revealed 30 carriers of the CD19 mutation. Lymphocyte subset counts were not significantly different between carriers and noncarriers in three different age groups (0-10 years; 11-18 years; adults). B cells of carriers had reduced CD19 and CD21 median expression levels, and had reduced proportions of transitional (0-10 years) and CD5 þ B cells (adults). CD19 carriers did not show clinical signs of immunodeficiency; they were well capable to produce normal serum Ig levels and had normal responses to primary and booster vaccinations. The frequency of mutated Vk alleles was not affected. Heterozygous loss of CD19 causes some changes in the naive B-cell compartment, but overall in vivo B-cell maturation or humoral immunity is not affected. Many antibody deficiencies are not monogenetic, but likely caused by a combination of multiple genetic variations. Therefore, functional analyses of immune cell function should be carried out to show whether heterozygous mutations contribute to disease.
Introduction
Primary antibody deficiency syndromes are a heterogeneous group of disorders in which the fundamental defect is an inability to produce effective antibody responses to pathogens. 1, 2 Consequently, the patients are highly susceptible to infections with encapsulated bacteria, and can have a high incidence of bronchitis and pneumonia, which often lead to progressive and irreversible lung damage. Initial diagnosis and subdivision into three categories is based on the reduction of serum immunoglobulin (Ig) levels in combination with the number of B cells in peripheral blood: 1, 2 (1) patients with strongly reduced B-cell numbers and serum Ig levels are defined as agammaglobulinemic; (2) patients with normal B-cell numbers, normal to high IgM, but severely reduced IgG and IgA suffer from a Hyper-IgM syndrome; and (3) patients with low to normal B-cell numbers and strongly reduced IgG, and IgA or IgM are diagnosed with a 'common variable immunodeficiency disorder' (CVID). In the last two decades, multiple gene defects have been identified that underlie these types of antibody deficiencies. 2, 3 In about 90% of patients diagnosed with agammaglobulinemia and about 75% of cases with a Hyper-IgM syndrome, the underlying genetic defect has been identified. 2 Whereas mutations have been described in patients diagnosed with CVID, [4] [5] [6] [7] [8] [9] [10] [11] [12] in over 90% of these patients no associated genetic defect has been found. In fact, in most CVID patients a complex genetic trade rather than a single affected gene is likely to contribute to development of the disease. For a full understanding, it will be essential to determine the functional effects of each associated genetic variant.
Homozygous CD19 mutations can underlie an antibody-deficiency syndrome. 5, 6 CD19 forms a complex with CD21, CD81 and CD225, and functions to lower the threshold for B-cell antigen receptor (BCR) signaling following antigen engagement. 13 Consequently, CD19-deficient and CD81-deficient patients were found to be defective in BCR stimulation and showed poor responses to vaccination. 5, 12 We identified a Turkish immunodeficient boy who is a cousin of the first identified Turkish CD19-deficient patient, and was homozygous for the same CD19 gene mutation (c.972insA). Because the two patients were born in large families with consanguineous marriages, we assumed that many of the family members would be carriers of the CD19 mutation, and consequently have reduced protein expression. 5 We hypothesized that CD19 expression levels regulate BCR signaling and, therefore, we set out to study peripheral B-cell development and antibody responses in carriers of the CD19 mutation.
Results

CD19 mutation analysis and clinical evaluation
We identified a CD19 deficiency in a 12-year-old Turkish boy with an antibody deficiency (patient ID558). CD19 mutation analysis showed homozygosity for the c.972insA mutation, which was found previously in a Turkish girl (patient ID037). 5 Subsequent analysis of the family history revealed that both children were related and born in large families with consanguineous marriages ( Figure 1) . To study the inheritance of the mutation, we selected 96 family members: 47 children (29 girls, mean age 10.3±4.3 years) and 49 adults (26 women, mean age 34 ± 11.9 years). None of the subjects were homozygous for the mutation; 30 were heterozygous for the mutation (15 children, 15 adults). There were no significant differences in age and gender between the carriers and noncarriers.
The 30 subjects who inherited the c.972insA mutation belonged to different branches of the large family tree ( Figure 1 ). Therefore, it is likely that multiple family members in generation III carried the mutation, and potentially even several in generation I. We concluded that the mutation originated before the indicated generation I and has been propagated over time throughout a large family in multiple individuals.
Clinical evaluation of all 96 individuals revealed recurrent upper and lower respiratory infections in 22 subjects (18 noncarriers and 4 carriers), but none of the 22 individuals were finally diagnosed with an immunodeficiency. Two carriers had asthma and one had experienced autoimmune hemolytic anemia. On the basis of the clinical evaluation of 30 carriers, it was concluded that the heterozygous CD19 mutation is not directly associated with clinical signs of an antibody deficiency.
Blood B-cell compartment Flow cytometric immunophenotyping of blood samples showed that total leukocyte, total lymphocyte, CD4
þ T-cell, NK cell and B-cell counts of all 96 subjects were within the normal ranges for age (data not shown). To compare leukocyte and lymphocyte subset numbers between carriers and noncarriers, we divided all subjects into three age groups (Supplementary Table  1 ): 0-10 years (group 1), 11-18 years (group 2) and adults (group 3). The total leukocyte, total lymphocyte, CD4
þ T-cell, NK cell and B-cell counts were not significantly different between carriers and noncarriers for all three age groups. Therefore, similar to homozygous loss of CD19, heterozygous loss of CD19 does not appear to grossly affect lymphocyte subset numbers.
The effects of heterozygous loss of CD19 on the CD19 complex were studied by flow cytometric analysis of CD19 and CD21 expression levels on B cells in all 96 subjects (Figure 2a ). CD19 median expression levels were significantly reduced in carriers (2.4-fold; Po0.0001) as compared with noncarriers as determined with two different monoclonal CD19 antibodies. Furthermore, CD21 median expression levels were 1.3-fold reduced in carriers as compared with noncarriers (Po0.0001). These results clearly show that two normal CD19 alleles are required to generate normal CD19 protein levels and subsequent CD19 complex formation with normal CD21 expression.
CD19-deficient individuals were shown to have altered blood B-cell compartments. Specifically, CD5
þ , IgD þ memory and IgD À memory B-cell subsets were found to be reduced. 5 In addition, flow cytometric immunophenotyping was carried out to study the relative frequencies of transitional, naive mature, natural effector, memory B cells and CD5 þ B cells (Figure 2 and Supplementary Table 1) . No significant differences were found between carriers and noncarriers for natural effector and memory B cells. Apparently, efficient memory B-cell formation can take place despite one mutated CD19 allele.
Within the naive B-cell compartment, several differences were observed. Both transitional and CD5
þ B cells showed a trend to be reduced in carriers of all three age groups ( Figure 2 ). These differences were significant for transitional B cells in group 1 (0-10 years) and CD5 þ B cells in group 3 (adults). All transitional B cells are CD5 þ . Therefore, these results suggest that both homozygous and heterozygous CD19 mutations affect the transitional B-cell homeostasis. Considering that similar trends were observed in all three age groups, these effects appear to be age independent.
Serum Ig levels
To study whether the reduced CD19 expression on blood B cells from carriers affected serum Ig levels, we compared the serum IgG, IgA and IgM levels between carriers and noncarriers for the three different age groups ( Figure 3 ). The median IgG levels were slightly lower for carriers as compared with noncarriers in all three age groups, but this difference was not significant. IgA and IgM serum levels were not different between carriers and noncarriers in age groups 1 and 3. However, carriers of group 2 had significantly increased serum IgA (2.3 g l À1 ) as compared with noncarriers (1.6 g l À1 ; P ¼ 0.017), whereas IgM serum levels were slightly reduced in carriers of group 2 (1.1 g l À1 ) as compared with noncarriers (1.6 g l
À1
; P ¼ 0.057). Despite the reduced CD19 expression levels, carriers of CD19 gene mutations are well capable of serum Ig production.
Somatic hypermutation analysis
Despite differences in the B-cell compartment, carriers of CD19 mutations are seemingly as capable as noncarriers in generation of memory B cells and serum Ig levels. To study whether the molecular processes initiated upon antigen recognition by B cells are normal, we studied somatic hypermutation (SHM) levels. The frequency of mutated Vk alleles was studied in the blood of nine noncarriers and six carriers (age range 11-17 years) using the Igk restriction enzyme hot-spot mutation assay. 12 In all individuals, a large proportion of the expressed Vk3-20 alleles was mutated and these values were within the range of healthy controls as described by Andersen et al. 12 with a median of 70% for noncarriers and 76% for carriers ( Figure 4 ). The frequency of mutated Humoral immunity in carriers of a CD19 mutation H Artac et al alleles was clearly reduced in both CD19-deficient patients (0 and 27%). Therefore, SHM levels appear not to be affected in carriers of a CD19 gene mutation.
Antibody response to vaccination
The total Ig production and SHM levels of Ig genes appeared to be normal in CD19 carriers. To determine whether the quantity and affinity maturation of specific antibody responses are affected, we studied the antibody responses to tetanus and rabies vaccinations in five noncarriers (age 11-17 years), five carriers (age 13-17 years) and the CD19-deficient patients (10-11 years). All children had previously been vaccinated in early childhood with tetanus according to the standard vaccination schemes. Therefore, the applied tetanus vaccination in this study can be regarded as a booster vaccination. As expected, most individuals had clearly detectable levels of anti-tetanus IgG antibodies before booster vaccination (Figures 5a and b) . These levels increased after booster vaccination in all carriers and noncarriers. In contrast, the anti-tetanus antibodies showed a decrease on booster vaccination for a CD19-deficient patient, ID558. This patient was unable to mount a proper response. The antitetanus IgG level in this patient was likely the result of previous intravenous administrations of Ig.
To study both the primary and booster responses to a neo-antigen, we vaccinated the same individuals twice with rabies. The IgG1 anti-rabies responses were similar for both noncarriers and carriers and in the same range as observed before in healthy adults (Figures 5c and d) . 15 Furthermore, on booster vaccination the avidity of antirabies IgG1 of both noncarriers and carriers increased and was comparable with normal healthy adults ( Figures  5e and f) . The two CD19-deficient patients showed an impaired antibody response to rabies, both quantitatively and qualitatively (avidity). In conclusion, in contrast to CD19-deficient patients, carriers of a CD19 mutation showed normal responses to primary and booster vaccinations with a T-cell-dependent antigen.
Autoreactive antibody levels
The incidence of autoimmune diseases is increased in CVID patients. Also, autoreactive antibodies have been found in CD19-deficient patients. 5, 6 To study whether defective CD19 alleles are associated with autoreactive antibody production, we measured anti-nuclear IgG antibodies in both CD19-deficient patients and 96 family members. Despite reduced total serum IgG levels, CD19-deficient patient, ID037, had high titers of anti-nuclear antibodies (ANAs; 1/640) measured at multiple time points, which were specific for SS-A. Patient ID558 was negative for ANA and of the 96 family members, 3/66 noncarriers and 1/30 carriers had ANAs of unknown specificity. Whereas CD19-deficiency might be associated with the production of autoreactive antibodies, heterozygous loss of CD19 appears to have no effect.
Discussion
In this study, the clinical and immunological effects of heterozygous loss of CD19 were determined in a large cohort of family members of two Turkish CD19-deficient patients. By DNA sequencing, 30 subjects were found to be heterozygous for the c.972ins(A) mutation in the CD19 gene, whereas 66 other subjects did not carry this mutation. B cells of carriers showed a profound reduction in CD19 and CD21 expression levels. Furthermore, the proportions of CD5 þ and transitional B cells among the total blood B-cell population were reduced. Moreover, despite altered serum Ig class distribution, memory B-cell formation, serum Ig production and antibody responses seemed normal as compared with noncarriers, Humoral immunity in carriers of a CD19 mutation H Artac et al and carriers of the CD19 mutation did not show any clinical signs of immunodeficiency. Therefore, it can be concluded that reduced CD19 expression because of heterozygous loss of CD19 leads to changes in the naive B-cell compartment, but is not associated with defects in antigen-induced B-cell maturation or humoral immunity. Our observations of reduced CD19 and CD21 membrane expression in 30 carriers of a CD19 gene mutation confirm and strengthen earlier observations. 5, 6 The 2.4-fold reduction of CD19 in carriers clearly showed that two functional alleles are required for normal CD19 membrane expression levels on B cells, and that the loss of one allele cannot be compensated for by the remaining functional allele. Furthermore, the 1.3-fold decrease in CD21 membrane expression in carriers shows the tight relation between CD19 and CD21 on mature B cells.
Childhood carriers of the CD19 gene mutation showed reduced numbers of transitional B cells. Transitional B cells are recent bone marrow emigrants that have to undergo selection against self-reactive antigens before developing into naive mature B cells. 16 This development is accompanied by homeostatic proliferation. 17 Why generation of transitional B cells would be affected by reduced CD19 expression is unclear. It could be related to the observed overall trends of reduction of CD5 þ B cells in carriers, as all transitional B cells are CD5 positive. 18, 19 The development of CD5 þ B1 B cells was severely decreased in the peritoneum of CD19-deficient mice. 20, 21 Whereas human CD5 þ B cells in the blood might not be the functional equivalence of mouse B1 B cells, they were equally affected in CD19-deficient mice and patients with CD19 homozygous mutations.
5 CD5 is a cell-surface receptor that has inhibitory effects on BCR signaling. 22 In this regard, CD5 could act to keep the fraction of autoreactive transitional B cells under control. The reduced expression of membrane CD19 increases the threshold for BCR stimulation. It is therefore possible that the generation or maintenance of CD5-positive transitional B cells is less relevant as a checkpoint to prevent development of self-reactive B cells in individuals with reduced CD19 expression levels.
We did not find an association between CD19 mutation carriership and autoimmune phenomena. A highly increased incidence (20-35%) of autoimmune disorders has been found in patients currently diagnosed with CVID. 23, 24 In fact, several CD19-deficient patients have high levels of autoantibodies either with or without an autoimmune disease. 5, 6, 25 Because only five CD19-deficient patients have been described so far, it cannot be concluded whether loss of CD19 is associated with increased autoimmunity. BCR-mediated signaling and Toll-like receptor-mediated signaling in precursor B cells are important for the removal of autoreactive B-cell receptors, as patients with genetic defects in BTK or MyD88 have been shown to have increased number of B cells carrying autoreactive BCRs. 26, 27 Because the CD19 complex is important for signaling by the BCR, it might have a similar role in the removal of B cells carrying autoreactive B-cell receptors. In our cohort of 30 carriers of a CD19 gene mutation, we did not find increased autoimmunity or increased levels of ANAs. Therefore, from our study, it can be concluded that a twofold reduction in CD19 membrane expression does not promote the development of autoimmunity. Figure 4 Somatic hypermutation levels. The frequency of mutated Vk3-20 alleles expressed by B cells in the blood was determined with the Igk restriction enzyme hot-spot mutation assay for nine noncarriers, six carriers and two CD19-deficient patients. No differences were seen for the frequencies of mutated alleles between noncarriers and carriers, which were all within the normal range for adults as determined by Andersen et al. 14 Both CD19-deficient patients showed clearly reduced frequencies of mutated alleles.
Because CD19 regulates the threshold for BCRdependent signaling, we hypothesized that reduced CD19 expression levels in carriers of a CD19 gene mutation would result in inefficient antibody responses. However, we did not observe any defects as compared with noncarriers with respect to the memory B-cell compartment, SHM levels, serum Ig levels or antibody responses on vaccination. Apparently, the twofold reduction in CD19 expression is not sufficiently severe to quantitatively or qualitatively impair immune function as observed for T-cell-dependent B-cell responses in homozygous CD19-deficient patients and mice. 5, 6, 20 Still, we cannot exclude that mild defects in antibody responses to less powerful (T-cell independent) antigens that exist in heterozygote carriers of CD19 gene defects.
We present evidence that heterozygous CD19 mutations are not associated with antibody deficiency in humans. Heterogeneity in clinical phenotype is a hallmark of many complex diseases such as CVID and may result from involvement of several genetic factors. Genetic linkage studies support the identification of candidate genes and mutations. [28] [29] [30] [31] We stress that, similar to our this study, functional analyses of immunity should be carried out to show whether heterozygous mutations indeed have an impact on immune function and, thereby, may contribute to disease.
In conclusion, despite reduced CD19 and CD21 expression and changes in the naive B-cell compartment, heterozygous loss of CD19 does not affect humoral immune responses and B-cell memory formation and is therefore unlikely to contribute to an antibody deficiency syndrome. Still, the stepwise approach as presented in this study to investigate the clinical and immunological effects of a mutated allele is necessary to support or rule out a role as a disease-underlying factor.
Materials and methods
Informed consent was obtained from all the subjects and parents of children for diagnostic workup of blood samples, and rabies and tetanus vaccinations. The study was approved by the medical ethics committee of Selçuk University in Turkey.
Clinical evaluation
Demographic (age, gender, consanguinity) and clinical information were gathered from 96 relatives of the two related Turkish CD19-deficient patients by a face-to-face questionnaire focusing on the 10 warning signs of suspecting primary immunodeficiency. 32 Flow cytometry Flow cytometric immunophenotyping of peripheral blood samples from 96 subjects was carried out to evaluate lymphocyte subsets, and CD19 and CD21 expression levels on B cells (41000 B-cell events per tube), on an LSRII using FACS DIVA analysis software (BD Biosciences, Santa Clara, CA, USA). The following B-cell subsets were defined:
þ IgD À memory and CD5 þ B cells.
DNA isolation and CD19 mutation analysis
The CD19 gene on chromosome 16 (16p11.2) spans 7.5 kb of genomic DNA and encodes a protein of 556 amino acids, including signal peptide. 33 To detect the c.972insA The shaded area represents the normal range for healthy adult controls and was determined in a previous study. 13 (e, f) The avidity index of antirabies IgG1 was measured 4 weeks after primary and secondary vaccinations. Due to the low anti-rabies IgG1 levels, the avidity index could not be measured for CD19-deficient patient ID558.
CD19 mutation, we PCR-amplified exon 6 from postFicoll blood granulocyte DNA and sequenced it on an ABI prism 3130 XL fluorescent sequencer (Applied Biosystems, Foster City, CA, USA). 5 Serum Ig and ANA levels Serum Ig levels (IgG, IgA and IgM) were measured in all 96 subjects with an immunoturbidimetric method (Hitachi analyzer; Roche, Mannheim, Germany).
Sera were tested for ANAs using indirect immunofluorescence at a 1:80 dilution on Hep-2000 slides (Immuno Concepts, Sacramento, CA, USA). All positive patterns were retested using serial dilutions to obtain an antibody titer, and tested for specific reactivity against SS-A, SS-B, dsDNA, RNP, SM, Scl70 and Jo-1 with FEIA (ImmunoCAP 250; Phadia, Uppsala, Sweden) and Immunoblot (INNO-LIA; Immunogenetics, Ghent, Belgium).
In vivo vaccination with rabies and tetanus vaccines Five carriers (age 11-17 years) and five noncarriers (age 10-17 years) were vaccinated once with tetanus vaccine and twice with the human diploid cell rabies vaccine (Institute Pasteur Merieux, Merk Sharp&Dohme, Lyon, France) according to standard protocols. Antibody levels and avidity were measured as described previously. 15 RNA isolation, cDNA synthesis and SHM analysis RNA was isolated from post-Ficoll peripheral blood mononuclear cell and reverse transcribed with random hexamers. SHM levels in peripheral blood B cells were determined using the Igk restriction enzyme hot-spot mutation assay as described by Andersen et al.
14 In short, Vk3-20 (A27) transcripts were amplified using a TETcoupled forward primer for the signal peptide region and an FAM-labeled reverse primer for the FR3 region. The 271-bp PCR product was digested by the restriction enzyme Fnu4HI (New England Biolabs, Ipswich, MA, USA). Unmutated alleles resulted in FAM-coupled fluorescent fragments of 106 or 109 bp, and mutated alleles in 244 bp fragments. The fraction of PCR products with mutations preventing cleavage was calculated as the proportion between the 244-bp fragment peak area and the sum of the peak areas of 244-, 106-and 109-bp fragments. Parallel digests of PCR products with DdeI were carried out to visualize DNA contamination by the presence of an FAM-coupled fluorescent 131 bp fragment. Throughout the study no DNA contamination was seen.
Statistics
Statistical analysis was carried out using a statistical package program (SPSS for Windows, Version 13.0; SPSS Inc., Chicago, IL, USA). The w 2 -test was used to examine differences with categorical variables. The other data were analyzed with the Kruskal-Wallis test and when significant differences were found (Po0.05), pair-wise comparisons were made using the Mann-Whitney U-test with Bonferroni procedure.
